Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients-Reference-Cited by-同舟云学术

Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients

Published:2013-10-03 Issue:12 Volume:58 Page:794-798
ISSN:1434-5161
Container-title:Journal of Human Genetics
language:en
Short-container-title:J Hum Genet

Author:

Hirasawa Akira,Zama Takeru,Akahane Tomoko,Nomura Hiroyuki,Kataoka Fumio,Saito Koichiro,Okubo Keisuke,Tominaga Eiichiro,Makita Kazuya,Susumu Nobuyuki,Kosaki Kenjiro,Tanigawara Yusuke,Aoki Daisuke

Publisher

Springer Science and Business Media LLC

Subject

Genetics(clinical),Genetics

Link

http://www.nature.com/articles/jhg2013105.pdf

Reference35 articles.

1. Rothenberg, M. L., Kuhn, J. G., Schaaf, L. J., Rodriguez, G. I., Eckhardt, S. G., Villalona-Calero, M. S. et al. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann. Oncol. 12, 1631–1641 (2001).

2. Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matsui, K. et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl Cancer Inst 83, 1164–1168 (1991).

3. Rothenberg, M. L., Kuhn, J. G., Burris, H. A. 3rd, Nelson, J., Eckhardt, J. R., Tristan-Morales, M. et al. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11, 2194–2204 (1993).

4. Fuchs, C. S., Moore, M. R., Harker, G., Villa, L., Rinaldi, D. & Hecht, J. R. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J. Clin. Oncol. 21, 807–814 (2003).

5. Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S. & Rustum, Y. M. Irinotecan in the treatment of colorectal cancer: clinical overview. J. Clin. Oncol. 19, 1501–1518 (2001).

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment;Seminars in Cancer Biology;2022-11

2. Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect;Clinical Pharmacokinetics;2022-09-30

3. Association of UGT1A1*6 , UGT1A1*28 , or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis;Clinical and Translational Science;2022-05-31

4. Mechanisms of chemoresistance and approaches to overcome its impact in gynecologic cancers;Overcoming Drug Resistance in Gynecologic Cancers;2021

5. Drug resistance in gynecologic cancers: Findings and underlying mechanisms;Overcoming Drug Resistance in Gynecologic Cancers;2021